首页> 美国卫生研究院文献>BMJ Open >Study protocol of a phase 2 dual-centre randomised controlled trial evaluating the effectiveness of probiotic and egg oral immunotherapy at inducing desensitisation or sustained unresponsiveness (remission) in participants with egg allergy compared with placebo (Probiotic Egg Allergen Oral Immunotherapy for Treatment of Egg Allergy: PEAT study)
【2h】

Study protocol of a phase 2 dual-centre randomised controlled trial evaluating the effectiveness of probiotic and egg oral immunotherapy at inducing desensitisation or sustained unresponsiveness (remission) in participants with egg allergy compared with placebo (Probiotic Egg Allergen Oral Immunotherapy for Treatment of Egg Allergy: PEAT study)

机译:研究方案的第2期双中心随机受控试验评估益生菌和蛋口免疫疗法在与安慰剂(益生蛋白过敏原口服免疫疗法)相比诱导脱囊炎或持续的反应(缓解)的潜伏细胞病毒和持续的反应(缓解)蛋过敏:泥炭研究)

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Egg allergy is the most common food allergy in children but recent studies have shown persistence or delayed resolution into adolescence. As there is currently no effective long-term treatment, definitive treatments that improve quality of life and prevent fatalities for food allergies are required. We have previously shown that a novel treatment comprising a combination of the probiotic Lactobacillus rhamnosus CGMCC 1.3724 with peanut oral immunotherapy (OIT) is highly effective at inducing sustained unresponsiveness, with benefit persisting to 4 years after treatment cessation in the majority of initial treatment responders. In this study, we plan to extend the probiotic food OIT platform to another allergen, namely egg. We describe the protocol for a phase 2, dual-centre, randomised, controlled trial evaluating the effectiveness of probiotic and egg OIT at inducing desensitisation or sustained unresponsiveness (remission) in participants with egg allergy compared with placebo.
机译:鸡蛋过敏是儿童最常见的食物过敏,但最近的研究表明持续或延迟分离到青春期。由于目前没有有效的长期治疗,所以需要改善生活质量和防止食物过敏的死亡的明确治疗。我们之前已经表明,具有花生口服免疫疗法(OIT)的益生菌乳酸杆菌CGMCC1.3724的组合的新型治疗在诱导持续的反应下,在大多数初始治疗响应者的治疗后持续到4年的益处。在这项研究中,我们计划将益生菌食品OIT平台扩展到另一种过敏原,即鸡蛋。我们描述了阶段2,双中心,随机,受控试验的方案,评估益生菌和蛋OIT在与安慰剂相比与鸡蛋过敏的参与者中持续的脱敏或持续反应(缓解)的益生菌和蛋效率的有效性。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号